Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Coronado Biosciences (NASDAQ:FBIO) has received a distressing two-star ranking.

With that in mind, let's take a closer look at Coronado and see what CAPS investors are saying about the stock right now.

Coronado facts

Headquarters (founded)

Burlington, Mass. (2006)

Market Cap

$258.5 million

Industry

Biotechnology

Trailing-12-Month EBITDA

($28.0 million)

Management

Chairman/CEO Harlan Weisman
CFO Lucy Lu

Trailing-12-Month Return on Capital

(63.4%)

Cash/Debt

$44.1 million / $14.3 million

Competitors

Abbott Labs
Biogen Idec

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 22% of the 23 members who have rated Coronado believe the stock will underperform the S&P 500 going forward.

Just last week, one of those Fools, All-Star zzlangerhans, showed a great deal of skepticism over Coronado's prospects:

Whipworm eggs to treat autoimmune disease might sound completely reasonable to some people, but I see it as farfetched to the border of insanity. If you wonder why high level executives and scientists would spend years pursuing a completely irrational scientific endeavor, my answer would be that I don't know but I see it happen all the time. The fact that Coronado management is confident does not make me confident. ... Topline results from the TRUST-1 phase II trial of the magic beans in ulcerative colitis are expected in the second half of 2013, so we don't have too long to wait.